市場調査レポート

商品コード

1771576

性感染症用分子診断の市場規模、シェア、動向分析レポート：製品別、用途別、技術別、地域別、セグメント予測、2025～2033年

Molecular Diagnostics For STD Market Size, Share & Trends Analysis Report By Product, By Application, By Technology, By Region, And Segment Forecasts, 2025 - 2033

出版日: 2025年06月13日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日

カスタマイズ可能

価格

Unprintable PDF & Excel (Single User License)

USD 5,950 877,506円

レポートPDF及びExcelを1名様のみがご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷はできません。

Printable PDF & Excel (5-User License)

USD 6,950 1,024,986円

レポートPDF及びExcelを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。

Printable PDF & Excel (Enterprise License)

USD 8,950 1,319,946円

レポートの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF及びExcelのテキスト等のコピー＆ペースト、印刷は可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.48円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

性感染症用分子診断市場サマリー

世界の性感染症（STD）用分子診断の市場規模は、2024年に33億6,000万米ドルと推計され、2025～2033年にかけてCAGR 8.35%で成長し、2030年には69億4,000万米ドルに達すると予測されます。クラミジア、淋病、梅毒、ヒトパピローマウイルス（HPV）などの性感染症の罹患率の増加は、市場成長を促進する重要な要因です。

正確かつ早期発見への需要が、分子診断ツールの普及に寄与しています。核酸増幅技術の向上や定期的なSTD検診に対する意識の高まりも市場拡大を後押ししています。この動向を受け、診断開発企業は、性感染症の病原体を迅速、多重、高スループットで検出する次世代分子検査に注力しています。最近の技術革新には、ポイントオブケア核酸増幅検査や、最小限の時間で正確な結果が得られるように設計されたポータブルPCRベース機器などがあります。例えば、2025年3月、Visby Medicalは、家庭用として承認された初の市販PCR診断機器であるWomen's Sexual Health Testの米国食品医薬品局（FDA）デノボ認可を取得しました。この手のひらサイズの機器は、クラミジア、淋病、トリコモナスに対する迅速で信頼性の高い検査を可能にし、検査室での処理を必要とせずに30分以内に結果を提供します。このような進歩は、信頼性の高い検査へのアクセス拡大、診断所要時間の短縮、早期かつ正確な検出による患者管理の強化という市場の焦点を反映しています。

さらに、分子診断研究の技術的進歩により、より高感度で特異的な性感染症標的検査の開発が可能になりました。アッセイ設計、サンプル処理、増幅技術における革新は、診断精度を向上させ、効果的な疾患管理に不可欠な偽陰性を減少させました。これらの進歩は、特に高リスク集団における無症候性感染や重複感染の検出における既存の課題解決に役立っています。さらに、診断機器メーカーや公衆衛生機関による継続的な研究投資は、分子診断パイプラインの拡大を支援し、多様なヘルスケア環境での利用拡大を促進しています。

進展が続いているとはいえ、STD用分子診断市場は、成長を制限しかねないいくつかの課題に直面しています。新しい分子診断検査の開発、検証、および規制当局の承認には多大な時間と資源が必要であり、メーカーは厳格な安全基準と性能基準に準拠する必要があります。これらの要因により、製品上市が遅れ、市場での入手が制限されることがあります。さらに、診断技術への一貫したアクセスを確保することは、特にヘルスケアのインフラが限られている地域では、物流上の困難を伴います。信頼できるサンプルの保管、輸送、熟練した人材が必要であるため、遠隔地や十分なサービスを受けていない地域での検査展開は複雑となります。これらの課題は、規制上のハードルに対処し、流通網を改善するための協調的な取り組みが必要であることを浮き彫りにしており、STD用分子診断へのアクセスを世界的に拡大することが求められています。

性感染症（STD）用分子診断市場シェア：地域別、2024年および2033年
北米
- 米国
- カナダ
- メキシコ
欧州
- 英国
- ドイツ
- フランス
- イタリア
- スペイン
- デンマーク
- スウェーデン
- ノルウェー
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- タイ
ラテンアメリカ
- ブラジル
- アルゼンチン
中東およびアフリカ
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- クウェート

第8章競合情勢

主要市場参入企業による最近の動向と影響分析
企業分類
企業ヒートマップ分析
企業プロファイル
- BD
- F. Hoffmann-La Roche Ltd
- Hologic Inc.
- Abbott
- Cepheid（Danaher）
- Qiagen
- OraSure Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- bioMerieux SA
- Thermo Fisher Scientific, Inc.
- Seegene Inc.
- DiaSorin SpA

図表

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Region, 2021 - 2033 (USD Million)
Table 4 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 5 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 6 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 7 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
Table 8 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 9 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 10 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 11 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 12 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 13 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 14 Canada Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 15 Canada Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 16 Canada Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 17 Mexico Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 18 Mexico Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 19 Mexico Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 20 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
Table 21 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 22 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 23 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 24 Germany Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 25 Germany Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 26 Germany Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 27 UK Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 28 UK Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 29 UK Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 30 France Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 31 France Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 32 France Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 33 Italy Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 34 Italy Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 35 Italy Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 36 Spain Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 37 Spain Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 38 Spain Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 39 Denmark Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 40 Denmark Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 41 Denmark Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 42 Sweden Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 43 Sweden Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 44 Sweden Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 45 Norway Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 46 Norway Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 47 Norway Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 48 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
Table 49 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 50 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 51 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 52 Japan Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 53 Japan Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 54 Japan Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 55 China Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 56 China Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 57 China Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 58 India Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 59 India Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 60 India Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 61 South Korea Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 62 South Korea Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 63 South Korea Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 64 Australia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 65 Australia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 66 Australia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 67 Thailand Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 68 Thailand Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 69 Thailand Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 70 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
Table 71 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 72 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 73 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 74 Brazil Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 75 Brazil Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 76 Brazil Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 77 Argentina Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 78 Argentina Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 79 Argentina Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 80 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
Table 81 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 82 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 83 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 84 Saudi Arabia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 85 Saudi Arabia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 86 Saudi Arabia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 87 South Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 88 South Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 89 South Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 90 UAE Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 91 UAE Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 92 UAE Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
Table 93 Kuwait Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 94 Kuwait Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 95 Kuwait Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market segmentation
Fig. 2 Data analysis models
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot-1
Fig. 14 Segment snapshot-2
Fig. 15 Competitive landscape snapshot
Fig. 16 Market trends & outlook
Fig. 17 Porter's five force analysis
Fig. 18 PESTEL analysis
Fig. 19 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Product outlook key takeaways
Fig. 20 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Product movement analysis
Fig. 21 Instruments & Services market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 22 Consumables (Reagents and kits) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 23 Softwares market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 24 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Application outlook key takeaways
Fig. 25 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Application movement analysis
Fig. 26 CT/NG testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 27 Syphilis testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 28 Gonorrhea testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 HSV testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 30 HPV testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 31 HIV testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 32 Trichomonas market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 33 Ureaplasma + Mycoplasma market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 34 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Technology outlook key takeaways
Fig. 36 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Technology movement analysis
Fig. 37 Laboratory Testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 38 Commercial/Private Labs market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 39 Public Health Labs market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 40 PoC testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 41 Regional marketplace outlook, 2024 & 2033 (USD million)
Fig. 42 Regional marketplace: Key takeaways
Fig. 43 North America
Fig. 44 North America market estimates and forecasts, 2021 - 2033
Fig. 45 U.S.
Fig. 46 U.S. market estimates and forecasts, 2021 - 2033
Fig. 47 Canada
Fig. 48 Canada market estimates and forecasts, 2021 - 2033
Fig. 49 Mexico
Fig. 50 Mexico market estimates and forecasts, 2021 - 2033
Fig. 51 Europe
Fig. 52 Europe market estimates and forecasts, 2021 - 2033
Fig. 53 UK
Fig. 54 UK market estimates and forecasts, 2021 - 2033
Fig. 55 Germany
Fig. 56 Germany market estimates and forecasts, 2021 - 2033
Fig. 57 France
Fig. 58 France market estimates and forecasts, 2021 - 2033
Fig. 59 Italy
Fig. 60 Italy market estimates and forecasts, 2021 - 2033
Fig. 61 Spain
Fig. 62 Spain market estimates and forecasts, 2021 - 2033
Fig. 63 Denmark
Fig. 64 Denmark market estimates and forecasts, 2021 - 2033
Fig. 65 Sweden
Fig. 66 Sweden market estimates and forecasts, 2021 - 2033
Fig. 67 Norway
Fig. 68 Norway market estimates and forecasts, 2021 - 2033
Fig. 69 Asia Pacific
Fig. 70 Asia Pacific market estimates and forecasts, 2021 - 2033
Fig. 71 China
Fig. 72 China market estimates and forecasts, 2021 - 2033
Fig. 73 Japan
Fig. 74 Japan market estimates and forecasts, 2021 - 2033
Fig. 75 India
Fig. 76 India market estimates and forecasts, 2021 - 2033
Fig. 77 Thailand
Fig. 78 Thailand market estimates and forecasts, 2021 - 2033
Fig. 79 South Korea
Fig. 80 South Korea market estimates and forecasts, 2021 - 2033
Fig. 81 Australia
Fig. 82 Australia market estimates and forecasts, 2021 - 2033
Fig. 83 Latin America
Fig. 84 Latin America market estimates and forecasts, 2021 - 2033
Fig. 85 Brazil
Fig. 86 Brazil market estimates and forecasts, 2021 - 2033
Fig. 87 Argentina
Fig. 88 Argentina market estimates and forecasts, 2021 - 2033
Fig. 89 Middle East and Africa
Fig. 90 Middle East and Africa market estimates and forecasts, 2021 - 2033
Fig. 91 South Africa
Fig. 92 South Africa market estimates and forecasts, 2021 - 2033
Fig. 93 Saudi Arabia
Fig. 94 Saudi Arabia market estimates and forecasts, 2021 - 2033
Fig. 95 UAE
Fig. 96 UAE market estimates and forecasts, 2021 - 2033
Fig. 97 Kuwait
Fig. 98 Kuwait market estimates and forecasts, 2021 - 2033
Fig. 99 Market share of key market players-
Fig. 100 Market participant categorization
Fig. 101 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market position analysis, 2024
Fig. 102 Strategic framework

Product Code: GVR-4-68040-619-4

Molecular Diagnostics For STD Market Summary

The global molecular diagnostics for sexually transmitted diseases (STDs) market size was estimated at USD 3.36 billion in 2024 and is projected to reach USD 6.94 billion by 2030, growing at a CAGR of 8.35% from 2025 to 2033. The increasing incidence of sexually transmitted infections such as chlamydia, gonorrhea, syphilis, and human papillomavirus (HPV) is a key factor driving market growth.

The demand for accurate and early detection contributes to the uptake of molecular diagnostic tools. Improvements in nucleic acid amplification technologies and growing awareness about regular STD screening are also supporting market expansion. Supporting this trend, diagnostic developers are concentrating on next-generation molecular tests that offer rapid, multiplexed, and high-throughput detection of sexually transmitted pathogens. Recent innovations include point-of-care nucleic acid amplification tests and portable PCR-based devices designed to deliver accurate results in minimal time. For instance, in March 2025, Visby Medical received U.S. Food and Drug Administration (FDA) De Novo authorization for its Women's Sexual Health Test, the first over-the-counter PCR diagnostic device approved for at-home use. This palm-sized device enables rapid, reliable testing for chlamydia, gonorrhea, and trichomoniasis, providing results within 30 minutes without needing laboratory processing. Such advancements reflect the market's focus on expanding access to reliable testing, reducing diagnostic turnaround time, and enhancing patient management through early and precise detection.

Moreover, technological progress in molecular diagnostic research has enabled the development of more sensitive, specific, and targeted tests for sexually transmitted infections. Innovations in assay design, sample processing, and amplification techniques have improved diagnostic accuracy and reduced false negatives, crucial for effective disease management. These advancements help address existing challenges in detecting asymptomatic infections and co-infections, especially in high-risk populations. In addition, continued investment in research by diagnostic manufacturers and public health organizations supports the expansion of molecular diagnostics pipelines and promotes wider availability across diverse healthcare settings.

Despite ongoing progress, the molecular diagnostics for STD market faces several challenges that may limit growth. The development, validation, and regulatory approval of new molecular tests require substantial time and resources, with manufacturers needing to comply with rigorous safety and performance standards. These factors often cause delays in product launches and restrict market availability. In addition, ensuring consistent access to diagnostic technologies presents logistical difficulties, especially in regions with limited healthcare infrastructure. The need for reliable sample storage, transportation, and skilled personnel complicates test deployment in remote or underserved areas. These challenges highlight the necessity for coordinated efforts to address regulatory hurdles and improve distribution networks to expand access to molecular diagnostics for STDs worldwide.

Global Molecular Diagnostics For STDs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global molecular diagnostics for sexually transmitted diseases (STDs) market report based on product, application, technology, and region.

Product Outlook (Revenue, USD Million, 2021 - 2033)
Instruments & Services
Consumables (Reagents and kits)
Softwares
Application Outlook (Revenue, USD Million, 2021 - 2033)
CT/NG Testing
Syphilis Testing
Gonorrhea Testing
HSV Testing
HPV Testing
HIV Testing
Trichomonas
Ureaplasma + Mycoplasma
Others
Technology Outlook (Revenue, USD Million, 2021 - 2033)
Laboratory Testing
- Commercial/Private Labs
- Public Health Labs
PoC testing
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Movement Analysis, 2024 & 2033 (USD Million)
4.3. Instruments & Services
- 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Consumables (Reagents and kits)
- 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Software
- 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Movement Analysis, 2024 & 2033 (USD Million)
5.3. CT/NG testing
- 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Syphilis testing
- 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Gonorrhea testing
- 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. HSV testing
- 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. HPV testing
- 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. HIV testing
- 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Trichomonas
- 5.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.10. Ureaplasma + Mycoplasma
- 5.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.11. Others
- 5.11.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Movement Analysis, 2024 & 2033 (USD Million)
6.3. Laboratory Testing
- 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.2. Commercial/Private Labs
  - 6.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.3. Public Health Labs
  - 6.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. PoC testing
- 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Regional Estimates & Trend Analysis

7.1. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Share, By Region, 2024 & 2033, USD Million
7.2. North America
- 7.2.1. North America Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3. Europe
- 7.3.1. Europe Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Japan Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. China
  - 7.4.3.1. China Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Australia
  - 7.4.5.1. Australia Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. South Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. UAE
  - 7.6.4.1. UAE Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. BD
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. F. Hoffmann-La Roche Ltd
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Hologic Inc.
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Abbott
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Cepheid (Danaher)
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Qiagen
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. OraSure Technologies, Inc.
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Bio-Rad Laboratories, Inc.
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. bioMerieux SA
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Thermo Fisher Scientific, Inc.
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/ Strategic Initiatives
- 8.4.11. Seegene Inc.
  - 8.4.11.1. Participant's Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Product Benchmarking
  - 8.4.11.4. Recent Developments/ Strategic Initiatives
- 8.4.12. DiaSorin S.p.A
  - 8.4.12.1. Participant's Overview
  - 8.4.12.2. Financial Performance
  - 8.4.12.3. Product Benchmarking
  - 8.4.12.4. Recent Developments/ Strategic Initiatives

性感染症用分子診断の市場規模、シェア、動向分析レポート：製品別、用途別、技術別、地域別、セグメント予測、2025～2033年

Molecular Diagnostics For STD Market Size, Share & Trends Analysis Report By Product, By Application, By Technology, By Region, And Segment Forecasts, 2025 - 2033

目次

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章性感染症（STD）用分子診断市場の変数、動向、および範囲

第4章性感染症（STD）用分子診断市場：製品別の推定・動向分析

第5章性感染症（STD）用分子診断市場：用途別の推定・動向分析

第6章性感染症（STD）用分子診断市場：技術別の推定・動向分析

第7章性感染症（STD）用分子診断市場：地域別の推定・動向分析

第8章競合情勢

List of Tables

List of Figures

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Variables, Trends, & Scope

Chapter 4. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Estimates & Trend Analysis

Chapter 5. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Estimates & Trend Analysis

Chapter 6. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Estimates & Trend Analysis

Chapter 7. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

性感染症用分子診断の市場規模、シェア、動向分析レポート：製品別、用途別、技術別、地域別、セグメント予測、2025～2033年

Molecular Diagnostics For STD Market Size, Share & Trends Analysis Report By Product, By Application, By Technology, By Region, And Segment Forecasts, 2025 - 2033

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 性感染症（STD）用分子診断市場の変数、動向、および範囲

第4章 性感染症（STD）用分子診断市場：製品別の推定・動向分析

第5章 性感染症（STD）用分子診断市場：用途別の推定・動向分析

第6章 性感染症（STD）用分子診断市場：技術別の推定・動向分析

第7章 性感染症（STD）用分子診断市場：地域別の推定・動向分析

第8章 競合情勢

List of Tables

List of Figures

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Variables, Trends, & Scope

Chapter 4. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Estimates & Trend Analysis

Chapter 5. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Estimates & Trend Analysis

Chapter 6. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Estimates & Trend Analysis

Chapter 7. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章性感染症（STD）用分子診断市場の変数、動向、および範囲

第4章性感染症（STD）用分子診断市場：製品別の推定・動向分析

第5章性感染症（STD）用分子診断市場：用途別の推定・動向分析

第6章性感染症（STD）用分子診断市場：技術別の推定・動向分析

第7章性感染症（STD）用分子診断市場：地域別の推定・動向分析

第8章競合情勢